Combination of avutometinib and defactinib offers new option where chemotherapy has often failed
Combination of avutometinib and defactinib offers new option where chemotherapy has often failed
Big capital flows into companies marrying AI with cancer treatments suggest early-stage clinical research is shifting its centre …
Oral brain-penetrant NLRP3 inhibitor and new collaborations place BioAge at center of metabolic aging drug development
Trial halt and valuation collapse trigger major workforce reduction at fibrosis-focused biotech
TRANQUILITY trial results strengthen case for pacibekitug as a potential quarterly IL-6 inhibitor for cardiovascular inflammation in chronic …
FORECAST-2 trial pioneers the use of tumor organoids for personalized treatment selection in bowel cancer, aiming to revolutionize …
Dual clinical studies reveal statistically meaningful benefits for patients with MSA, highlighting a leap forward for disease-modifying treatment …
Botensilimab and balstilimab combinations deliver unprecedented tumor responses across multiple cancer types, fueling optimism for harder-to-treat colorectal, breast, …
In a world-first, an infant with a fatal genetic disorder receives a custom, in vivo CRISPR therapy, showcasing …
Breakthroughs in personalized therapies and AI-driven tools are reshaping how cancer is diagnosed and treated, promising better outcomes …
